ABSTRACT
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and
afflicts about 10% of the population over 60. Biomarker research in neuro-
degenerative disorders using blood and cerebrospinal fluid (CSF) is focused on
specific targets: early detection, differential diagnosis (classification), tracking of
disease progression, and evaluation of therapeutic strategies. With the currently
approved antidementia drugs and with the development of novel disease
modifying therapeutic strategies (secondary prevention), it is of particular
clinical interest to establish early diagnostic and preclinical prognostic
biomarkers of AD.
